HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS)
AssigneeThe University of North Carolina at Chapel Hill
InventorsEliane WAUTHIER, Tsunekazu OIKAWA, Timothy Anh-Hieu DINH, Praveen SETHUPATHY, Lola M. REID
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.
Claims15
1-19. (canceled)
A method of treating a patient determined to have human fibrolamellar hepatocellular carcinoma (hFL-HCC) by administering to the patient an effective amount of at least one therapeutic that decreases expression of at least one of C10orf128, CA12, CREB3L1, GALNTL6, IRF4, ITPRIP, KCNE4, NOVA1, OAT, PAK3, PCSK1, PHACTR2, RPS6KA2, SLC16A14, TMEM163, or TNRC6C.
22-23. (canceled)
Dependencies are inferred from the claim text.